OMEICOS Therapeutics
Anne Konkel has worked for two companies: OMEICOS Therapeutics GmbH since 2013, where they are currently the Head of Technology & External Research and Development, and the Max Delbrück Center from 2008 to 2013, where they were a PhD Student.
Anne Konkel attended Universität Greifswald from 2003 to 2008, where they earned a Diplom in Humanbiologie.
OMEICOS Therapeutics
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.